124 related articles for article (PubMed ID: 29286146)
1. Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.
Akiyama Y; Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ashizawa T; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Yamaguchi K
Oncol Rep; 2018 Mar; 39(3):1125-1131. PubMed ID: 29286146
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
[TBL] [Abstract][Full Text] [Related]
4. Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.
Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Iizuka A; Nonomura C; Ohshima K; Urakami K; Kusuhara M; Nagashima T; Sugino T; Yamaguchi K; Akiyama Y
J Dermatol; 2017 Oct; 44(10):1156-1159. PubMed ID: 28452169
[TBL] [Abstract][Full Text] [Related]
5. Classification of tumor microenvironment immune types based on immune response-associated gene expression.
Kondou R; Iizuka A; Nonomura C; Miyata H; Ashizawa T; Nagashima T; Ohshima K; Urakami K; Kusuhara M; Yamaguchi K; Akiyama Y
Int J Oncol; 2019 Jan; 54(1):219-228. PubMed ID: 30387832
[TBL] [Abstract][Full Text] [Related]
6. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
Afkhami M; Schmolze D; Yost SE; Frankel PH; Dagis A; Amanam IU; Telatar M; Nguyen K; Yu KW; Luu T; Pillai R; Aoun PA; Mortimer J; Yuan Y
PLoS One; 2019; 14(11):e0224726. PubMed ID: 31693690
[TBL] [Abstract][Full Text] [Related]
7. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
9. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
10. Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling-Project HOPE.
Akiyama Y; Kondou R; Iizuka A; Ohshima K; Urakami K; Nagashima T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2016; 37(4):233-42. PubMed ID: 27544999
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
12. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
15. Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu D; Lin JR; Robitschek EJ; Kasumova GG; Heyde A; Shi A; Kraya A; Zhang G; Moll T; Frederick DT; Chen YA; Wang S; Schapiro D; Ho LL; Bi K; Sahu A; Mei S; Miao B; Sharova T; Alvarez-Breckenridge C; Stocking JH; Kim T; Fadden R; Lawrence D; Hoang MP; Cahill DP; Malehmir M; Nowak MA; Brastianos PK; Lian CG; Ruppin E; Izar B; Herlyn M; Van Allen EM; Nathanson K; Flaherty KT; Sullivan RJ; Kellis M; Sorger PK; Boland GM
Nat Med; 2021 Jun; 27(6):985-992. PubMed ID: 33941922
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
[TBL] [Abstract][Full Text] [Related]
17. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
[TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]